Drugs / HB-01
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05071430 Comparator | Feb → Dec 2022 | panic disorder | HB BioTech, LLC | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HB-01 | “Approximately 40 patients will receive HB-01 active study drug.” NCT05071430 ↗ |